ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.

If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence. On this news, Disc Medicine's stock price fell 22% on February 13, 2026.